



## Using HTA Elements on Inpatients in Ukraine

Olha Zalis'ka, Prof.  
Olena Mandrik, MSc., PhD Candidate

Danylo Halytsky Lviv National Medical University, Ukraine;  
Erasmus University Rotterdam, the Netherlands

### Health Care System Characteristics


- ✓ Governmental expenditures on Health Care System: 3.2% of GDP (2011)
- ✓ Post-Semashko model
- ✓ In-hospital financing through central budget, regional budgets, "State programs"
- ✓ Budgets covers 38.5% of needs

Ministry of Health, 2010


### Normative Documents Developed Using HTA Elements

- ✓ State Formulary
- ✓ Governmental drugs register
- ✓ National register of the drugs and medical supplies of major importance
- ✓ Order from Cabinet of Ministers of Ukraine from 05.09.1996 p. № 1071 «The procedure of pharmaceuticals' purchases by the governmental establishments" (last amended 28.03.2011 )
- ✓ State programs demand evidence argumentation

## Formulary System in Ukraine



## Financing of State Programs in 2010 (thousands €)



## Role of Oncology in Health Care


- ✓ In Ukraine more than 860,000 people with oncologic condition
- ✓ Chernobyl impact (thyroid cancer)
- ✓ 38-40% of people with oncologic conditions die during first year after diagnosis
- ✓ 35% are working-age population
- ✓ Expenses on treatment of oncologic conditions are growing quicker than general expenses on drugs

Cancer register, 2010

## Oncology Drugs Provision

- ✓ Cross-integrated Governmental program "National Health for 2002-2011"
- ✓ State program on the treatment of oncologic diseases for the period 2010-2016 (Law of Ukraine № 1794-VI from 23.12.2009 )
- ✓ Clinical standards harmonized with EU, ASCO, NCCN
- ✓ National Cancer Institute (from 03.02.09 №67/2009)
- ✓ National Cancer Register (from 1989)

### Financing of State Program "Oncology" (million €)



### Drug Purchases in Oncology 2010

#### Reasoning:

- Experts opinion
- Choice: innovations or generics with lower price

**Low-price Generics:** tamoxifen (0.01 €/DDD; 17 400 packs); melphalan (0,13 €/DDD; 2875 packs)

**High-price Innovations:** bortezomib (1897 €/DDD; 239 packs); rituximab (691 €/DDD; 70 packs)

### Project "Improvement of Oncologic Help to Ukrainian Population"

#### Objectives:

1. Improvement of oncologic diseases prophylactics
2. Improvement of diagnostics and special treatment methods

#### Goals:

1. Improve regulatory base
2. Provide free-of-charge specialized treatment for oncologic patients
3. Improve registration of sick on cancer
4. Improve clinical indicators by 5-30%

New amendment of Order #208 from 30.12.1992

### Inpatient Costs in Oncology

- ✓ Average costs estimation 1000-1500 €/patient/year
- ✓ Largest part of costs (70-80%) → drug treatment

#### Governmental Expenditures:

- ✓ Cost of 1 patient in specialized hospital: 428 €
- ✓ Cost of 1 hospitalization day: 29 €
- ✓ Cost of 1 hospitalization day excluding drug cost: 17 €
- ✓ Low-cost treatment option in case of limited financing is argued in the clinical standards


## Role of Diabetes in Health Care

- ✓ Prevalence is 1,183,011 patients, including 7,666 children (01.2010)
- ✓ In the last 15 years the prevalence rate has doubled
- ✓ Insulin-dependent are 185,978 people (15.7%), including 7,546 children (98.4%)

## Goals of State Diabetes Program in Ukraine for 2009-2013

- ✓ Reimbursement for adults from 3% to 11%, for children from 10% to 30%
- ✓ Decrease complications by up to 30%
- ✓ Decrease hospitalization rate of children by 10% each year
- ✓ Decrease death rate by 10%

## Financing of State Diabetes Program in Ukraine for 2009-2013



## Diabetes Drugs Provision

- ✓ Ukrainian producers "Indar", "Farmak", "Darnitsa": supplies of analogues, insulin for regular patients
- ✓ Imported insulin in pens, genetically engineered forms from Novo Nordisk, Lilly France, Sanofi Aventis, TEVA Pharmaceutical: supply for children, teenagers, pregnant women
- ✓ Test-strip for all patients (twice/month), glucose meters for all pregnant

Reasoning: Experts opinion, program control by the Order MOH #716 from 25.08.2010

## Conclusions

- ✓ HTA elements in Ukrainian HCS are not obligatory, but used in state formulary, clinical protocols, order on drugs purchase #1071
- ✓ Oncology and diabetes are branches with goal financing that stays stable during the last years
- ✓ Specificity of Ukrainian system: attempts to use better care under very limited financing
- ✓ Evidence-based approach (as defining HC needs, drugs and equipment purchases) used more often in Ukraine
- ✓ Legislation on obligatory HTA use is still currently missing in Ukraine